The 2024 Clinical Practice Guidelines for the Management of Hypertension in China address 44 key clinical issues and offer 98 evidence-based recommendations for hypertension prevention and management.
This article highlights 9 key insights from the 2024 Clinical Practice Guidelines for the Management of Hypertension in China to assist physicians in clinical practice.
In September 2024, 3 leading committees—the Chinese Society of Cardiology under the Chinese Medical Association, the Hypertension Committee of the Cross-Straits Medicine Exchange Association, and the Cardiovascular Disease Prevention and Rehabilitation Committee of the Chinese Association of Rehabilitation Medicine—jointly released the Clinical Practice Guidelines for the Management of Hypertension in China (hereinafter referred to as the “Guidelines”). These Guidelines address 44 key clinical issues closely related to the prevention and management of hypertension, offering a total of 98 evidence-based recommendations. This article highlights and provides an in-depth analysis of the 9 key insights from the Guidelines to assist physicians in better understanding its most critical content.
Wang et al. (Wed,) conducted a review in Hypertension. Clinical Practice Guidelines for the Management of Hypertension in China was evaluated. The 2024 Clinical Practice Guidelines for the Management of Hypertension in China address 44 key clinical issues and offer 98 evidence-based recommendations for hypertension prevention and management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: